Please assess the completion status of the following clinical trial:

Trial Title: Sugammadex and Neostigmine at Residual Neuromuscular Blockade

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients ASA physical status I - III~* Patients over 18 years~* Patients scheduled for general anesthesia with intubation using rocuronium~* Patients having given informed consent to the study~Exclusion Criteria:~* Anatomic and functional malformations with expected difficult intubation~* Known or suspected neuromuscular disease~* Significant hepatic or renal dysfunction~* Known or suspected history or family history of disposition to malignant hyperthermia~* Known or suspected allergy towards sugammadex, anesthetics, muscle relaxants, or other drugs used for general anesthesia~* Use of drugs that interfere with muscle relaxants~* Patients, included in another trial within the last 30 days~* Patients, with legal guidant~* Patients with contraindication towards the use of Sugammadex, neostigmine or glycopyrrolate~* Patients, which have already participated in a sugammadex trial~* Pregnant women (exclusion of pregnancy: postmenopausal status, negative β- HCG screen, status post tubal ligation)~* Breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sgx 0.25 (Type: None): Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
- Sgx 0.5 (Type: None): Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
- Sgx 0.75 (Type: None): Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
- Sgx 1.0 (Type: None): Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
- Sgx 1.25 (Type: None): Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
- Neo 10 (Type: None): Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
- Neo 25 (Type: None): Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
- Neo 40 (Type: None): Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
- Neo 55 (Type: None): Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
- Neo 70 (Type: None): Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
- Saline (Type: None): Saline group: Saline as placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).